Merck Vioxx Detailing Should Have Addressed VIGOR Risks – FDA’s Jenkins
This article was originally published in The Tan Sheet
Executive Summary
Merck should have included risk findings from the VIGOR study when promoting Vioxx to physicians before the data was added to labeling, FDA Office of New Drugs Director John Jenkins told a congressional hearing May 5
You may also be interested in...
Opportunity Knocks For Supplements Pitched As Problem Solvers
Dietary supplement firms, even working within the limits of FDA's claims regulations, can capitalize on more opportunities to promote their products as problem solvers, according to market consultants
Opportunity Knocks For Supplements Pitched As Problem Solvers
Dietary supplement firms, even working within the limits of FDA's claims regulations, can capitalize on more opportunities to promote their products as problem solvers, according to market consultants
Opportunity Knocks For Supplements Pitched As Problem Solvers
Dietary supplement firms, even working within the limits of FDA's claims regulations, can capitalize on more opportunities to promote their products as problem solvers, according to market consultants